G. Sonpavde

The Double Antibody Drug conjugate (DAD) Phase I trial: Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.

T. K. Choueiri, B.A. McGregor, G. Sonpavde, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.

B. McGregor, P. Grivas, A. Apolo, 2024, Journal of Clinical Oncology.

Vaccine approaches to treat urothelial cancer

G. C. Giudice, G. Sonpavde, 2024, Human vaccines & immunotherapeutics.

Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.

R. Satkunasivam, Michael Geng, Sanjana Ranganathan, 2024, Urologic oncology.

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.

A. LaCasce, A. Drakaki, S. Kambhampati, 2024, Clinical lymphoma, myeloma & leukemia.

Factors predictive of recurrence, metastasis and death in node-negative penile squamous cell carcinoma: A retrospective multicentre cohort study.

C. Schmults, M. Mossanen, F. Murad, 2024, Journal of the European Academy of Dermatology and Venereology : JEADV.

The evolving treatment landscape of metastatic urothelial cancer.

G. Roviello, M. Catalano, G. Sonpavde, 2024, Nature reviews. Urology.

660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)

G. Sonpavde, E.P. Hamilton, N. Lakhani, 2023, Annals of Oncology.

Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.

M. S. van der Heijden, M. D. Galsky, M. Claps, 2024, Journal of Clinical Oncology.